Jim Simons's top dividend stocks (July 2026) include Sinovac Biotech, Ltd. (SVA), a biopharmaceutical company that focuses on the research, development, and manufacturing of vaccines against human infectious diseases.

Jim Simons is the founder of Renaissance Technologies, a prominent hedge fund management firm based in East Setauket, New York. He is widely recognized for his pioneering quantitative investment approach, which utilizes complex mathematical models and automated algorithms to navigate global financial markets.

Sinovac Biotech, Ltd. (SVA)

Sinovac Biotech is a China-based biopharmaceutical firm specializing in vaccine development for infectious diseases like influenza and hepatitis. The company operates production facilities that support large-scale manufacturing for global distribution. The current value of this position in Jim Simons’s portfolio stands at $8.49M. Currently, the stock offers a dividend yield of 8.5% with a TTM dividend rate of 110.0. Its discounted cash flow value is estimated at 15.63.

Here's an overview of Jim Simons's trades in Sinovac Biotech, Ltd.:

Novabay Pharmaceuticals Inc (NBY)

NovaBay Pharmaceuticals is a medical products company that focuses on commercializing anti-infective products for the eye care market. Their primary focus includes products designed to treat conditions like blepharitis and dry eye syndrome. Jim Simons holds a position currently valued at $121.7K in his portfolio. The firm maintains a TTM dividend rate of 0.8, and investors can expect a dividend yield of approximately 3.6%. Furthermore, its discounted cash flow is calculated at 1.23.

Here's an overview of Jim Simons's trades in Novabay Pharmaceuticals Inc:

Net Lease Office Properties (NLOP)

Net Lease Office Properties is a real estate investment trust that manages a portfolio of office properties primarily leased to corporate tenants. The company focuses on assets with long-term, net-lease structures across various geographic markets. Within the current portfolio, this holding represents a value of $649.99K. The company presents a dividend yield of 1.97% and a TTM dividend rate of 22.35, while the discounted cash flow value is noted at 32.6.

Here's an overview of Jim Simons's trades in Net Lease Office Properties:

Centessa Pharmaceuticals plc (CNTA)

Centessa Pharmaceuticals is a clinical-stage pharmaceutical company working on a diversified portfolio of therapeutic programs. The firm operates using a unique hub-and-spoke model to develop medicines across various disease areas, including rare diseases and oncology. This position is currently worth $7.49M in Simons’s portfolio. With a TTM dividend rate of 38.0, the stock has a dividend yield of 0.94%, and it currently carries an analyst price target of 42.0 alongside a discounted cash flow value of 0.48.

Here's an overview of Jim Simons's trades in Centessa Pharmaceuticals plc:

CommScope Holding Company Inc (COMM)

CommScope Holding Company provides infrastructure solutions for communications, data, and entertainment networks. They manufacture a wide range of products including antennas, cables, and wireless systems for telecommunications providers and enterprise networks. The current value of the position in Jim Simons’s portfolio is $41.52M. While the TTM dividend rate is currently 0.0, the stock offers a dividend yield of 0.79% and shows a discounted cash flow value of 2.99.

Here's an overview of Jim Simons's trades in CommScope Holding Company Inc: